Literature DB >> 6167620

Human gamma interferon production by leukocytes induced with monoclonal antibodies recognizing T cells.

P von Wussow, C D Platsoucas, M Wiranowska-Stewart, W E Stewart.   

Abstract

The murine monoclonal antibody OKT3 (IgG2), which recognizes the majority of human E-rosette-forming cells, was found to induce interferon (IFN) production in human peripheral lymphocytes in vitro. This IFN was classified as IFN-gamma by virtue of its acid stability, nonneutralization by antisera recognizing human IFN-alpha and beta, and non-cross-reactivity on bovine kidney cells. OKT3 elicited considerable IFN-gamma yields at a concentration of 1 ng/ml, at which only very low mitogenesis of the lymphocytes measured by 3H-thymidine incorporation was seen. The IFN-gamma activity appeared beginning 3 to 6 hr after stimulation and reached its maximum after 36 hr. Anti-human Lyt3, anti-human Lyt2, or anti-human Lyt1 monoclonal antibodies, recognizing all or the majority of the E-rosette-forming cells, did not elicit IFN-gamma production. The OKT4 monoclonal antibody, which defines a subpopulation of T cells containing cells with helper activity, induced marginal levels of IFN-gamma. In contrast, OKT8 monoclonal antibody (defining cytotoxic/suppressor cells) as well as monoclonal or heterologous antibodies recognizing histocompatibility antigens or surface immunoglobulin failed to induce IFN-gamma production. Heterologous anti-thymocyte globulin or anti-lymphocytic serum were effective IFN-gamma inducers. Cell separation studies of the leukocytes demonstrated that E-rosette-forming cells are responsible for production of IFN-gamma induced by OKT3. Treatment of the leukocyte suspension with OKt3 monoclonal antibody plus complement abolished IFN-gamma production induced by this antibody. These results demonstrate that the OKT3 antibody recognizing an antigen present on the majority of the E-rosette-forming cells alone is sufficient to induce IFN-gamma production. OKT3-positive cells are apparently the producers of this IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6167620

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Regulation of immunity by anti-T-cell antibodies.

Authors:  D Wofsy
Journal:  West J Med       Date:  1990-09

2.  Role of monocytes in anti-CD3-induced T-cell DNA synthesis: effect of chloroquine and monensin on anti-CD3-induced human T-cell activation.

Authors:  B Vayuvegula; K Ohira; S Gollapudi; S Gupta
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

3.  HBsAg-induced interferon-gamma secretion in T cells from asymptomatic HBsAg carriers and HB-immune donors in vitro.

Authors:  S P Sylvan; U B Hellström
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

Review 4.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

5.  The role of T3 in the activation of human T cells.

Authors:  A Weiss; J Imboden; R Wiskocil; J Stobo
Journal:  J Clin Immunol       Date:  1984-05       Impact factor: 8.317

6.  Biological effects of antibodies to lymphocyte surface receptors.

Authors:  J W Goding
Journal:  Springer Semin Immunopathol       Date:  1982

7.  Analysis of CD3 antigen expression in patients with ataxia-telangiectasia.

Authors:  B Boutin; D K Wagner; D L Nelson
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

8.  Immune interferon in serum and synovial fluid in rheumatoid arthritis and related disorders.

Authors:  M DeGré; O J Mellbye; O Clarke-Jenssen
Journal:  Ann Rheum Dis       Date:  1983-12       Impact factor: 19.103

9.  Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells.

Authors:  R Devos; H Cheroutre; Y Taya; W Degrave; H Van Heuverswyn; W Fiers
Journal:  Nucleic Acids Res       Date:  1982-04-24       Impact factor: 16.971

Review 10.  The interferons.

Authors:  J L Toy
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.